• Home >
  • Publications >
  • Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer

Adjuvant Trastuzumab Emtansine (T-DM1) and Concurrent Radiotherapy for Residual Invasive HER2-positive Breast Cancer

1 Dec 2020American Journal of Clinical Oncology

DOI : 10.1097/coc.0000000000000769

Authors

Zita Zolcsák, Delphine Loirat, Alain Fourquet, Youlia M. Kirova